Skip to content

Caligan Partners LP

Follow

13F filer, CIK 1727492, NEW YORK, NY

Caligan Partners LP reported $1,634,072,026 across 26 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 78.92% of the portfolio.

Accepted , ingested 13F-HR 0001420506-26-002879

Period
2026-09-30
Reported value
$1.63B
Holdings
26
Top 10 weight
78.92%
New
3
Sold out
5

Part of the filer group Caligan Partners LP

  • JOHNSON DAVID EDWARD
How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
OBXnew+886,281$12.2M
EPRXnew+1,163,010$10.6M
IMCRadded+290,824$8.81M
FTHadded+260,743$7.75M
IVAadded+1,022,744$3.77M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
XENEexited-889,944-$53.7M
MBXexited-200,000-$11M
ARTVreduced-255,068-$1.82M
IRDreduced-116,112-$562K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001420506-26-002879, largest first. % of portfolio is the value over $1,634,072,026, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 465,000 shares; 2025Q2: 636,835 shares; 2025Q3: 1,064,249 shares; 2025Q4: 1,283,900 shares; 2026Q1: 1,652,808 shares; 2026Q2: 1,961,795 shares; 2026Q3: 1,961,795 shares 1,961,795$403M24.64%0Timeline
LQDALIQUIDIA CORPORATIONQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 8,118,592 shares; 2025Q1: 8,118,592 shares; 2025Q2: 8,118,892 shares; 2025Q3: 8,118,892 shares; 2025Q4: 8,118,892 shares; 2026Q1: 8,118,892 shares; 2026Q2: 8,118,892 shares; 2026Q3: 8,118,892 shares 8,118,892$246M15.03%0Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 752,167 shares; 2025Q1: 1,269,119 shares; 2025Q2: 1,674,400 shares; 2025Q3: 1,451,924 shares; 2025Q4: 1,451,924 shares; 2026Q1: 1,461,924 shares; 2026Q2: 1,557,924 shares; 2026Q3: 1,557,924 shares 1,557,924$154M9.44%0Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,704,815 shares; 2026Q1: 2,060,719 shares; 2026Q2: 2,188,636 shares; 2026Q3: 2,188,636 shares 2,188,636$125M7.62%0Timeline
EXELEXELIXIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,525,730 shares; 2025Q1: 1,525,730 shares; 2025Q2: 1,525,730 shares; 2025Q3: 1,525,730 shares; 2025Q4: 1,553,262 shares; 2026Q1: 1,553,262 shares; 2026Q2: 1,553,262 shares; 2026Q3: 1,553,262 shares 1,553,262$90.7M5.55%0Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 3,729,895 shares; 2026Q1: 2,408,798 shares; 2026Q2: 2,500,103 shares; 2026Q3: 2,501,246 shares 2,501,246$62.4M3.82%+1,143Timeline
ADMAADMA BIOLOGICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,636,609 shares; 2025Q4: 3,012,508 shares; 2026Q1: 4,756,511 shares; 2026Q2: 5,725,007 shares; 2026Q3: 5,875,007 shares 5,875,007$58.9M3.61%+150,000Timeline
IMCRIMMUNOCORE HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,381,317 shares; 2026Q3: 1,672,141 shares 1,672,141$50.6M3.1%+290,824Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 833,333 shares; 2025Q4: 881,533 shares; 2026Q1: 1,635,023 shares; 2026Q2: 3,163,866 shares; 2026Q3: 3,268,303 shares 3,268,303$50.1M3.07%+104,437Timeline
LBRXLB PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,438,070 shares; 2026Q2: 1,438,070 shares; 2026Q3: 1,509,621 shares 1,509,621$49.6M3.04%+71,551Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,193,981 shares; 2026Q3: 2,193,981 shares 2,193,981$45.2M2.76%0Timeline
VORVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 925,067 shares; 2026Q1: 1,925,066 shares; 2026Q2: 1,925,066 shares; 2026Q3: 1,925,066 shares 1,925,066$36.7M2.25%0Timeline
IVAINVENTIVA SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,000,000 shares; 2026Q1: 4,974,906 shares; 2026Q2: 8,163,191 shares; 2026Q3: 9,185,935 shares 9,185,935$33.9M2.07%+1,022,744Timeline
IRDOPUS GENETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 6,075,028 shares; 2026Q2: 6,077,084 shares; 2026Q3: 5,960,972 shares 5,960,972$28.9M1.77%-116,112Timeline
AURAAURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 200,000 shares; 2025Q3: 227,174 shares; 2025Q4: not reported; 2026Q1: 229,864 shares; 2026Q2: 4,298,248 shares; 2026Q3: 4,590,253 shares 4,590,253$28.8M1.76%+292,005Timeline
ANIKANIKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,435,130 shares; 2025Q1: 1,435,130 shares; 2025Q2: 1,435,130 shares; 2025Q3: 1,435,130 shares; 2025Q4: 1,435,130 shares; 2026Q1: 1,435,130 shares; 2026Q2: 1,435,130 shares; 2026Q3: 1,435,130 shares 1,435,130$28.2M1.73%0Timeline
SABSSAB BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 7,967,207 shares; 2026Q2: 7,967,207 shares; 2026Q3: 8,736,898 shares 8,736,898$27.7M1.69%+769,691Timeline
SGMTSAGIMET BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,500,000 shares; 2026Q3: 2,794,484 shares 2,794,484$27.6M1.69%+294,484Timeline
FTHFAETH THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 126,002 shares; 2026Q2: 629,467 shares; 2026Q3: 890,210 shares 890,210$26.5M1.62%+260,743Timeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 25,000 shares; 2025Q2: 189,950 shares; 2025Q3: 696,825 shares; 2025Q4: 944,257 shares; 2026Q1: 1,276,968 shares; 2026Q2: 806,986 shares; 2026Q3: 910,749 shares 910,749$19.9M1.22%+103,763Timeline
OBXOBSIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 886,281 shares 886,281$12.2M0.74%newTimeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,163,010 shares 1,163,010$10.6M0.65%newTimeline
ARTVARTIVA BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,736,111 shares; 2026Q3: 1,481,043 shares 1,481,043$10.5M0.65%-255,068Timeline
VRCAVERRICA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 923,910 shares; 2025Q4: 923,910 shares; 2026Q1: 923,910 shares; 2026Q2: 923,910 shares; 2026Q3: 923,910 shares 923,910$4.43M0.27%0Timeline
TCGXTCGX ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 200,000 shares 200,000$2.5M0.15%newTimeline
CLRBCELLECTAR BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 469,998 shares; 2026Q3: 469,998 shares 469,998$865K0.05%0Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
XENEXENON PHARMACEUTICALS INC889,944$53.7Mshares
RVMDREVOLUTION MEDICINES INC251,800$47.2Mcall
MBXMBX BIOSCIENCES INC200,000$11Mshares
AGIOAGIOS PHARMACEUTICALS INC90,000$3.34Mcall
ADMAADMA BIOLOGICS INC300,000$2.51Mcall

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001420506-26-002879 base2026-11-16